Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of LBVE013 and LBVE014 in Healthy Adults
NCT02892812Phase 1Completed
- Sponsor
- LG Chem
- Start
- Sep 2016
- Primary completion
- Nov 2016
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of LBVE013 and LBVE014 in pneumococcal infection (3 arms), sponsored by LG Chem. Primary endpoints: Solicited adverse events at 7 days, Unsolicited adverse events at 4 weeks and 1 more. Started Sep 2016; status: completed.
02
Drugs
LBVE013LBVE014
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT02892812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02892812.